Skip to main content
PLOS One logoLink to PLOS One
. 2024 Jan 9;19(1):e0296713. doi: 10.1371/journal.pone.0296713

Challenges with pediatric antiretroviral therapy administration: Qualitative perspectives from caregivers and HIV providers in Kenya

Michala Sliefert 1, May Maloba 2, Catherine Wexler 1,*, Frederick Were 3, Yvonne Mbithi 3, George Mugendi 3, Edward Maliski 4, Zachary Nicolay 4, Gregory Thomas 5, Shadrack Kale 2, Nicodemus Maosa 2, Sarah Finocchario-Kessler 1
Editor: Petros Isaakidis6
PMCID: PMC10775971  PMID: 38194419

Abstract

Background

Current formulations of pediatric antiretroviral therapy (ART) for children with HIV present significant barriers to adherence, leading to drug resistance, ART ineffectiveness, and preventable child morbidity and mortality. Understanding these challenges and how they contribute to suboptimal adherence is an important step in improving outcomes. This qualitative study describes how regimen-related challenges create barriers to adherence and impact families.

Methods

We conducted key informant interviews (KIIs) with 30 healthcare providers and 9 focus group discussions (FGDs) with a total of 72 caregivers, across three public hospitals in Siaya and Mombasa Kenya. The KIIs and FGDs were audio recorded, translated, and transcribed verbatim. The transcripts were hand coded based on emergent and a-priori themes.

Results

Caregivers discussed major regimen-related challenges to adherence included poor palatability of current formulations, complex preparation, and administration (including measuring, crushing, dissolving, mixing), complex drug storage, and frequent refill appointments and how these regimen-related challenges contributed to individual and intrapersonal barriers to adherence. Caregivers discussed how poor taste led to child anxiety, refusal of medications, and the need for caregivers to use bribes or threats during administration. Complex preparation led to concerns and challenges about maintaining privacy and confidentiality, especially during times of travel. Providers corroborated this patient experience and described how these challenges with administration led to poor infant outcomes, including high viral load and preventable morbidity. Providers discussed how the frequency of refills could range from every 2 weeks to every 3 months, depending on the patient. Caregivers discussed how these refill frequencies interrupted work and school schedules, risked unwanted disclosure to peers, required use of financial resources for travel, and ultimately were a challenge to adherence.

Conclusion

These findings highlight the need for improved formulations for pediatric ART to ease the daily burden on caregivers and children to increase adherence, improve child health, and overall quality of life of families.

1.0 Introduction

The World Health Organization (WHO) guidelines call for all infants and children living with HIV to initiate antiretroviral therapy (ART) immediately after diagnosis [1]. Globally, 1.7 million pediatric patients (<15 years) require such treatments [2]. In Kenya, current first line ART regimens include AZT+3TC+NVP for children under 4 weeks of age (available in syrup), ABC+3TC+LPV/r for children 4 weeks to 3 years of age (ABC/3TC is available in tablet only, while LPV/r is available in syrup or table), and ABC+3TC+EFV for children 3–14 years of age (available in tablets, only) [3]. These current pediatric ART formulations pose significant barriers to ART adherence which contribute to ART ineffectiveness, drug resistance, and preventable child morbidity and mortality [46].

Regimen-related barriers to pediatric ART adherence affecting caregivers include complex dosing and administration requirements and risk of stigma and unintentional disclosure of HIV status. Current formulations require caregivers to measure and then prepare several drugs per dose which creates multiple opportunities for dosing errors or spillage that may hinder treatment efficacy [7]. This process is both time-consuming and conspicuous [7, 8]. This can result in inadvertent HIV status disclosure and stigma if friends or family discover the routine. Frequent weight and age related dosing changes further increase complexity [1] Primary regimen-related barriers affecting child/ infant ART adherence are inability to safely ingest solid tablets and the poor palatability of liquid formulations as either syrups or tablets reconstituted with water or breastmilk [711]. It is difficult to ensure delivery of an effective dose because infants and young children often resist ingestion, and can spit out liquid formulations administered via syringe [10].

Pediatric ART syrups are packaged in large bottles that are conspicuous when leaving the hospital, traveling, or storing within the home [7]. In many lower resource areas, including Kenya, ABC+3TC syrups (fixed-dose combination antiretroviral medication of Abacavir and Lamivudine, current first line pediatric medication for children <30kg in Kenya) [12] are not reliably available, thus tablets are crushed and dissolved in water as part of the treatment regimen. In some cases, this also requires boiling water to make it potable, adding to the burden and cost (for fuel) of ART preparation and administration for children. In settings with high HIV stigma and low disclosure rates, the current standard of pediatric ART care creates many barriers that often result in missed doses and low adherence, which can result in poor clinical outcomes for the child [7].

Our team is exploring alternative delivery strategies for pediatric ART and sought to understand challenges experienced with the regimens currently available in Kenya. Here, we describe how regimen-related challenges to pediatric ART pose challenges to families. This study is part one of a three-phase study with the overall objective of informing the design and development of alternative delivery mechanisms for pediatric ART regimens that will mitigate current barriers to improve adherence and optimize child health and survival. Next phases of the study will include integrating feedback into formulation and packaging prototypes and seeking stakeholder feedback on prototypes to finalize design elements.

2.0 Methods

This study describes challenges of ART administration for caregivers and providers through caregiver focus groups and provider key informant interviews (KIIs). Caregivers were eligible to participate in focus group discussions if they cared for a child living with HIV less than 10 years old and received HIV care for their child at one of the study hospitals (Bondo Referral Hospital in Siaya County, Ambira Sub-County Hospital in Siaya County, and Port Reitz Sub-County Hospital in Mombasa County). Both facility leaders and county ministries of health were sensitized on study goals and procedures and approved the study prior to implementation. These facilities were chosen because our team had established study infrastructure and working relationships there and they represented various health facility levels and regions. Caregivers were recruited by mentor mothers (mothers living with HIV who have been through PMTCT and EID services and serve as peer health advisors) or providers with established clinical care relationships with clients at the study sites. Providers were eligible for interviews if they routinely participated in pediatric HIV care (including counseling, ART prescription or dispensing, HIV clinical care) at one of the study sites. Participants were purposefully selected to represent caregivers over a range of child ages and providers with a variety of HIV care provision roles within the hospital. No eligible caregiver or provider refused participation in the study.

Participants provided written informed consent in compliance with IRB approvals at the University of Kansas Medical Center (STUDY00147024) and University of Nairobi (P457/06/2021). Caregiver informed consent documents and FGD guides were available in English, Luo, and Swahili and all documents and translations were approved by the IRB at the University of Nairobi. Provider informed consent documents and interview guides were available in English only, as all healthcare providers were fluent in English. During the informed consent process, the interviewer explained the purpose of the study, risks and benefits of the study, and emphasized that study participant was optional. Immediately after informed consent was provided but prior to the focus groups or KIIs, surveys with each participant were conducted to capture socio-demographics characteristics of providers and caregivers. Informed consent interviews and surveys occurred in a private area of the hospital and were conducted by a research assistant in English, Swahili, or Luo, per the participant’s preference. Focus groups and KIIs lasted approximately 90 or 30 minutes, respectively. Participants were provided $10 remuneration in appreciation for their time and contributions and soda was to each provided to each participant during the KII and FGD

Focus groups and interviews occurred from February to April of 2022. Focus groups and interviews were conducted by authors and study managers SB, NM, or a research assistant in a private area of the study hospital. Only the participant(s) and facilitator were present during the FGD or KII. Providers had interacted with study coordinators SB and NM prior to the interviews as part of other, ongoing research studies; however, caregivers did not have a previous relationship with the interviewers. All interviewers received training on the purpose of the study and qualitative methods. No other authors had access to participant identifying information.

Focus groups and interview guides probed about challenges with the current pediatric antiretroviral regimen. Guides were reviewed by Kenyan pediatricians (FW, YM) and nurses (MM) for acceptability. Focus groups and interviews were audio recorded and transcribed. For focus groups conducted in Kiswahili or Luo, transcripts were translated into English. Two analysts (MS and CW) coded transcripts based on a priori themes related to how characteristics of the ART regimen created individual-level and interpersonal barriers to adherence. Two analysts met periodically to refine the codebook and develop consensus. Analysts coded the transcripts and developed memos for each code to summarize the most salient themes, in this case challenges with HIV medication regimen. Excel was used to organize codes. Field notes were not taken, and transcripts were not returned to participants for comment or correction.

3.0 Results

A total of 9 focus groups were conducted with 72 total caregivers (mean age 37.3 years old, range 18–74) who provided care for n = 83 children (mean age 4.7 years old, range 5 months-18 years old; the caregiver to the 18-year-old also cared for younger children) living with HIV across three hospitals in Kenya. The majority of caregivers were parents (60.6%) and the majority of caregivers were female (83.3%). Twenty out of the 83 children cared for (24%) knew their HIV status. About 76% of the caregivers were living with HIV. Additionally, 30 KIIs were conducted with healthcare providers who provide pediatric HIV care across the same three hospitals (10 providers per hospital). The healthcare providers included clinical officers, mentor mothers, community health volunteers, nurses, and others, with a mean time in healthcare of 9.85 years. See Tables 1 and 2 for full caregiver and provider characteristics. Table 3 outlines key characteristics of caregiver FGD.

Table 1. Caregiver characteristics.

Gender N %
    males 12 16.7%
    Females 60 83.3%
Relationship to Child
    Grandparent 14 19.7%
    Aunt 8 11.3%
    Parent 43 60.6%
    Other 1 1.4%
    Sibling 3 4.2%
    Step mother 2 2.8%
    Non-family treatment support 1 1.4%
Number of HIV+ Children in Care
    1 61 84.7%
    2 10 13.9%
    3 1 1.4%
Child’s Disclosure Status
    Disclosed status to anyone but caregiver 69 95.8%
"I am the only one who gives the child his/her ART"
    TRUE 23 31.9%
Weekly household income
    <500 32 44.4%
    500–750 18 25.0%
    750–1000 9 12.5%
    1000–2500 9 12.5%
    >2500 4 5.6%
Level of education
    No school 2 2.8%
    Some Primary 24 33.3%
    Completed Primary 19 26.4%
    Some Secondary 11 15.3%
    Completed Secondary 13 18.1%
    Some college/university 3 4.2%
Caregiver HIV Status
    HIV+ 55 76.4%
    HIV- 16 22.2%
    Unknown 1 1.4%

Table 2. Provider characteristics.

Sex
    Female 19 63.3%
Provider role
    Mentor Mother 3 10.0%
    Pharmaceutical Technologist 3 10.0%
    CHV 3 10.0%
    Nurse 7 23.3%
    Clinical Officer 6 20.0%
    Hospital Administrator 3 10.0%
    County Administrator 1 3.3%
    Peer educator 2 6.6%
    Counselors 2 6.6%

Table 3. FGD characteristics.

FGD Site N Child age*
1 Bondo 8 2–5
2 Bondo 11 1–2
3 Bondo 11 6–10
4 Bondo 6 ≤1
5 Ambira 9 2–5
6 Ambira 10 6–10
7 Ambira 4 ≤2
8 Port Reitz 6 ≤5
9 Port Reitz 7 5+

*Targeted age categories were caregivers of children <1, 1–2, 2–5, and 6–10. However, age categories were combined at smaller sites.

3.1 Overview of results

Both caregivers and providers discussed how regimen-related characteristics posed challenges to caregivers and are, thus, collectively referred to throughout the results as “participants” when themes aligned. When findings differed amongst participant type, “caregiver” or “provider” is used to differentiate themes unique to each group.

Participants described how ART medications came in two primary formulations: syrups and tablets. Very young children mostly received syrups. Older children received tablets that were either crushed and dissolved in liquid for administration or as they got older, swallowed whole.

Participants discussed how regimen-related characteristics led to individual and intrapersonal challenges and impacted their family. The four primary regimen-related challenges with current formulations included: (1) poor taste, (2) complex preparation and administration, (3) required cold storage, and (4) frequent refills. Each of these regimen-related characteristics created additional challenges for the caregiver and child.

3.1.1 Poor taste

The poor taste of the pediatric ART was a salient theme among both caregivers and providers. Participants described how the bitterness of ART contributed to poor adherence, child refusal of the medication (running away/hiding, spitting out, vomiting) and ultimately strained the relationship between the caregiver and child. If the child vomited or spat out the ART, some caregivers discussed not knowing how much medication the child received and questioned whether they should add an additional dose.

The palatability is not good, and as you know, children love tasteful things and when you give them drugs that are not tasteful, they spit it out. It becomes difficult to administer the drug, so you don’t even know whether the child or children have gotten the correct dosage. (KII_ODS_KII07)

Because of the medications poor taste, administration was often described as a “battle”, with children refusing to take the medication, getting anxious around times of medication administration, and spitting out the medicine because of its poor taste. Many described how their child would run, hide, fight, or cry due to the unease around ART administration. “It reaches within a point where if the child sees the mother taking the bottle, he/she will just run away crying that the medication is bitter and that they don’t want it. (Hosp3_KII08).

Caregivers also described how the process of drug administration not only stressed their child but also caused them stress, anxiety, and guilt and strained the child-caregiver relationship.

They lose control and become unhappy for a very long time to the extent that I could also shed tears because after giving the drugs the baby becomes sullen and sad which makes me question what kind of life my child is going to have. That used to disturb me a lot. It is challenging. We are giving them drugs, but it is challenging. (Hosp2_FGD2_ID04)

To increase palatability, many caregivers mixed the solution with porridge, honey, sugar, or the syrup formulation, but “sometimes the doctors recommend we put it in milk or porridge, and when they notice it’s in the porridge, he won’t take it. And when dissolved in milk, he won’t even take a sip.” (Hosp1_FGD1_ID01). Caregivers described how adding sweeteners helped ease anxiety around administration, but they could not always afford the mixers, making administration even more difficult when they were unavailable: “She only likes tea, and it becomes hard for us, sometimes we don’t have sugar, because of lack of money and the child has to take the medication so this one is usually a challenge. (Hosp2_FGD1_ID03).

Caregivers also described different ways in which they could enhance their child’s cooperation through bribes or threats. Caregivers used instant rewards like sugar, honey, and phone time, or future rewards to motivate medication adherence: “I have to entice the child with a promised gift. I have to promise her that after taking medication, I will buy for her French fries” (Hosp2_FGD3_ID08). Although many caregivers utilized bribes, some discussed how bribes can be counterproductive if they cannot be maintained and provided every day, as their child would refuse to take the medication without the bribe.

“I don’t like giving mine honeybecause when I don’t have the honey and I must give the medicine, she will ask for honey… .” (Hosp1_FGD2_ID06)

A handful of caregivers explained that their child responded best to threats of either physical violence or restriction of leisure activities: “The child usually starts crying once he sees the medication so I have to scare the child by holding a cane so that they can take the medication. (Hosp2_FGD3_ID09). The caregivers who use threats during administration expressed an increase in their anxiety around ART but continue to do it, as it was an effective way to increase cooperation.

3.1.2 Complex preparation and administration

Caregivers described how the process of preparing and administering pediatric ART could take up to an hour to complete, twice a day, which placed a large burden on them. Tablets were described as the most complex to prepare, requiring them to first cut and crush the tablet then measure, dissolve, and mix the formulation. Each of these steps introduced opportunities for error.

I prepare porridge and then crush the medication then I take porridge and pour on the bottle cup and add the medication I had crushed, once I do this, I add porridge on top then give the child, I divide the medication into two, I give the first half first then the rest again with porridge, because when taken like that it is too bitter, so that is what I do.” (Hosp3_FGD1_ID06).

When a child was too small to take a full dose, caregivers were required to cut the tablet to give the proper dose. Although the tablets have marks indicating where the tablet needed to be broken, it did not always break in the proper spot, forcing the caregiver to choose whether to underdose or overdose because “Sometimes it breaks wrongly, forcing you to give ¾ instead of a ½ the tablet and …You just give it like that.” (Hosp1_FGD1_ID03)

After measuring the proper dose, the tablet was crushed and dissolved in water. However, tablets were described as difficult to crush and did not dissolve well, leaving the mixture sticky and layered: “It is hard for him to swallow and when chewing it sticks on his teeth. Sometimes he even spits the tablet. (Hosp1_FGD1_ID04)”

Given it’s complexity both caregivers and providers preferred medication administration to be done by the same person each day. Occasionally caregivers described how they must delegate the task to a trusted family member, friend, or older sibling that was aware of the child’s HIV status. They explained how the complexity of medication preparation and administration led them to “think that they might not give the drug well, so I have to call and confirm that the child has been given medication. (Hosp2_FGD3_ID09) Providers specifically noted that children living with HIV with primary caregivers who rely heavily on secondary caregivers, tend to have higher viral loads at checkups. This can be due to knowledge gaps, forgetfulness, and complexity of administration: “knowledge gap is there since the grandmother is not that learned so maybe sometimes reading the instructions is not easy for them, and they also have other priorities to attend to (Hosp2_KII04).”

Caregivers across all focus groups expressed a strong desire to keep their child’s HIV status private from those in the community, only disclosing the status to close friends and family, due to the stigma surrounding HIV. Fear of disclosure due to complex medication administration process made traveling difficult for children with HIV and their caregivers, as their caregivers struggle with how to carry the medication and properly prepare and administer it discreetly. Caregivers explained that traveling regularly made them question whether they should delay medication administration or risk disclosing their child’s status.

When there is a funeral at home and you attend it, when it comes time to give the child medication and there are some relatives who are unaware of your status, when you take out the medication to give to the child, they ask a lot of questions. It forces us to skip giving the child their medication to avoid the questions.” (Hosp2_FGD2_ID03)

Furthermore, this complex preparation and administration sometimes interfered with daily schedules, especially in situations where caregivers worked early mornings or late evening or if the children were in school. In the morning, the difficulty came if they needed to re-administer the medication if the child vomited, and in the evening, the difficulty was with getting home at the proper time to administer the medication.

I also had a challenge with the timing, especially if the child is going to schoolyou find that to administer the drugs, the child needs to eat, and sometimes the child will vomit after taking the drug… where you’ll have to wait for a while, before re-administering the drug…. and maybe you are running late.” (Hosp1_FGD2_ID01)

Together, the need to administer medications twice daily, the complex process of preparation and administration, and the “battles” that occurred at medication administration times, presented multiple opportunities for participant’s HIV status to be discovered by neighbors and family members. Caregivers explained many ways ART administration can inadvertently disclose their child’s status including: the sound of the pill bottles rattling in their purse, traveling monthly to refill medication, not allowing visitors in the house in the evenings, and having the child repeatedly question why they need daily medication.

So, when I want to give the baby the drugs, I always like to be alone and when I hear footsteps approaching; I’d want to know who it is. I just tell them I’m a bit busy and tell them to wait a while until I’m done. Personally, I’m not scared but this is my child’s life and her privacy.” (Hosp2_FGD2_ID04).

As caregivers begin the process of HIV disclosure to their child, either in part or in whole, it allowed the children to take part in their health and hold some responsibility. Once children understood the importance of the medication, the caregivers explained how it aided in the process of administration, even if their children still refused to swallow tablets whole.

I told mine that his body is invaded by viruses, and the drug is meant to make them inactive. If he does not take his medication, the virus will become active and affect him. He is well informed and aware that he can get sick if he does not adhere to his medication. (Hosp1_FGD2_ID03)

Caregivers with older children explained how the process of administration got easier with age. Not only were the challenges of taste and cooperation were minimized among older children who were able to swallow pills whole, but caregivers explained the children as young as six or seven had begun taking responsibility for their own or their sibling’s medication adherence.

Since one is 7 years old and can read, she is even able to administer the medication to the younger sibling, as she takes hers.

3.1.3 Storage

Of the medications discussed, all required a storage environment that was cool, dry, and away from direct sunlight, with the syrups specifically requiring refrigeration. Providers discussed how improper storage of the medication led to a decreased efficacy of the drug. “So actually, that has led to high viral loads because they are taking medication that not… that is not well stored. The condition has been compromised, the quality.” (Hosp2_KII08).

When caregivers did not have access to a refrigerator in their home, they described how they improvised cool areas to store the medication. Caregivers stored the medication in a cool jug of water or in a sandy hole in the ground. Each of these storage methods required frequent attention to ensure the medication environment does not get too warm and will not be discovered by young children or visitors.

I took a tin of sand and water and kept in in a cool place in my bedroom, so once I had sealed the bottle tightly, I would insert the bottle in the water, so I made sure that I kept on changing the water so that it does not become warm. (Hosp3_FGD2_ID03)

The strict storage environments also made it difficult in times of travel, as these strategies were not discreet and impossible to maintain on public transport. Tablets, however, could be kept in drawers, cupboards, or even in a handbag while traveling.

3.1.4 ART refill frequency and stockouts

The frequency of ART refill varied depending on child age and current viral load, because providers utilize medication refills as checkups to monitor weight-based dosing and medication adherence. Younger children and those with high viral loads had 2-week refill appointments, while the others varied from one to two months between appointments. Providers utilized refill appointments to check adherence by pill counts. Providers emphasized that an individualistic approach to each situation was important in determining the frequency of ART refill. The frequent refills posed multiple challenges for caregivers, as they had work commitments and responsibilities outside of the home.

There was a time that every month, my two girls had to miss their classes because of going for the refills, but it reached a point where I started skipping going with them to the clinic. Whenever they ask, I would tell them that, they were sitting for exams…I came all alone for about 5 months. You know, it even aroused my neighbors’ curiosity, they would always ask; “What’s the matter that makes you take the children to the hospital every month? (Hosp1_FGD1_ID04).

Many caregivers struggled to get fare required for transport, getting time off from work, and making their child miss school. The caregivers felt obligated to justify why their child was missing school and why they were missing work: “Also, it is very challenging to the school going kids. You will lie to the teacher today, but what will you tell him tomorrow? (Hosp1_FGD1_ID02).

Providers described how supply stockouts or shortages exacerbated the complexity of ART administration. When a pediatric drug stockout would occur, the providers were forced to hand out adult versions of the medication, which led to prescribing large, bitter pills that were difficult to accurately dose. Supply shortages would require caregivers to (1) increase frequency of trips to the hospital to collect smaller quantities of drugs, (2) seek drugs from private institutions at a cost to them, or (3) skip doses.

And the challenge we have now … there is low supply or there are no pellets around. What we have remaining in form of lopinavir is now the bigger tablets for the adults. In that situation we are stuck on what to do. Because you cannot resolve to maybe going to the bigger tablets and breaking it. You won’t know the exact quantity that you have given them. So, supplies are a challenge.” (Hosp3_KII06).

In times of supply shortages, children could be prescribed a syrup and tablet at the same time, or to be switched from one to the next at refill appointments. Providers noted that a child on multiple formulations led to confusion and mix-ups on administration. They emphasized that caregivers did the best they can with the time/skill they have, but improper handling of the drugs still led to suboptimal outcomes. For example, certain tablets cannot be crushed, but “here is a situation whereby there is a dilemma between giving a whole tablet and the child will refuse to swallow completely and it would go to waste or you crush it and compromise the effectiveness of drug and at least deliver something to this child (Hosp3_KII10).”

3.1.5 Challenges to adherence: In context

The many challenges discussed above were accentuated by financial constraints, religion, educational background, work status, and responsibilities outside the home that affected the caregiver’s ability to appropriately administer ART: “Most of these clients you find that from where they come from, they are not financially stable (KII_ODS_Bondo_02). It was not uncommon for the caregivers to have scarce resources and be forced to choose between whether to spend money on transportation and medication or food: Sometimes the caregiver doesn’t have money to come to the facility and completing tasks of the caregivers. (Hosp2_KII05).

The topic of access to information, education, counseling, and knowledge influenced provision of pediatric ART was a common occurrence in the provider interviews, but not as salient in the caregiver focus group discussions. Providers documented the challenge with proper measuring and administration of medication via primary or secondary caretakers who were illiterate or had a low education level: “I would not say illiterate for lack of a better term, but the level of education determines if they dispense the right volume, so maybe the child is overdosed or underdosed because of lack of knowledge on how to titrate (Hosp3_KII03).”

In addition to challenges with administration, a lack of knowledge about HIV and opposing religious beliefs made it difficult to convince caregivers that their child requires medication. Providers mentioned that these caregivers can go through a denial stage where they do not believe their child will become sick from HIV or need medication until opportunistic diseases takeover: “Some of them will tell you that their church does not accept use of medication, so the child and mother will not use the medication for a long time, so if they notice they have been overwhelmed by opportunistic diseases, that is when the lady or the child is brought back to the clinic, then you start again from there.” (Hosp3_KII01).

4.0 Discussion

Studies have shown that approximately 50% of Kenyan pediatric patients on ART have interruptions in their treatment lasting greater than 48 hours [13], with 48% being lost to follow up within 5 years [14]. This study explored the challenges that current standard of care pediatric ART administration presents to caregivers, children, and healthcare providers. The testimony from the stakeholders (caregivers and providers) highlighted the emotional toll that adhering to life-saving medication can have on both caregivers and children.

Long term medication adherence is a complex dynamic influenced by both the caregiver’s approach and the child’s acceptance and is a process that shifts as the child ages [15]. While studies have shown that greater caregiver involvement in medication administration leads to better adherence outcomes, as the child ages some responsible for medication is shifted to the child. Many programs aimed at transitioning children to adult care start at 12, 15, 18 years of age or even older [16]. Even amongst older children, readiness to take on responsibility for medication adherence is dependent on several factors including personal characteristics and mental health of the child, family structure, pre-transition adherence, disclosure of HIV status, and the caregiver must be able to assess these factors accurately when beginning to allow the child to take responsibility. Our study–and others–suggest that this shift may begin much earlier, with children as young as 6 or 7 beginning to take responsibility for their own medication adherence. Simplification of medications will help improve treatment adherence among children who may need to take on this responsibility before they are developmentally ready [17]. However, the need for caregiver support remains critical at every age and there is a strong link to positive caregiver involvement and their child’s adherence [15, 18, 19].

The complexity of ART administration was a salient theme in our results, with caregivers and providers lamenting the complex process of measuring and administering syrups or crushing tablets and mixing with food or drink multiple times per day. Simplifying ART regimens can improve adherence in both children and adults [2023]. ART regimens can be simplified through reducing the number of doses required per day and minimizing the pill burden or liquid volume associated with a single dose to improve adherence. In the past several years, several new delivery mechanisms have been explored and developed to ease the burden of administration. These include nanoparticle and dispersible tablets that can be mixed with food and beverage that studies have shown to be effective and acceptable, especially to younger children [24]. In addition, new promising advances in pediatric ART may improve long term adherence among children and alleviate the strain on the relationship between caretakers and children living with HIV. These advances include and buccal films [25], long-acting subcutaneous, intramuscular, or implant formulations and microarray patches [2630]. While these long-acting formulations may overcome many of the challenges associated with current formulations, they may introduce other challenges including inability to adjust to frequent weight-based dosing changes that occur in early childhood, pain and irritation at the injection site, and potential for stigma due to large patches [31].

Our team is developing oral dissolvable strips (ODS) [32] containing WHO recommended regimens for infants and children that feature several characteristics that reduce barriers to ART adherence: simplified drug preparation and administration, easily adaptable dosing to accommodate infant growth, and discreet packaging. The strip will be ready-to-use: caregivers adhere an ODS to the palate, inner cheek, or tongue for rapid dissolution in saliva. In pre-clinical studies, ODS formulated with prophylactic and therapeutics doses of ARV showed in-vitro and in-vivo bioequivalence to standard formulations [33]. Due to the current barriers, providers and caregivers were enthusiastic about being a part of the conversation to brainstorm better ways to administer ART. The results of this study reinforce the importance of creating a novel, user-centered design for pediatric ART to increase adherence, decrease stress, and overall improve the quality of life of both patients and caregivers treating HIV. This paper is part one of a three-part study that aims to take information from these FGDs and provider interviews to create prototypes of oral dissolvable strips (ODS) for pediatric ART treatment. In future steps, the team will develop ODS and packaging prototypes and present to stakeholders (caregivers, children, and providers) for feedback and finalization of design element.

A few limitations should be noted. The participants in the FGDs were caregivers who were actively engaged in their child’s ART care and were willing to participate in a focus group discussion regarding HIV, thus, had disclosed to someone. These caregivers may not represent the larger community, including those who are unengaged in their child’s HIV care, who remain undisclosed, and who are not comfortable speaking about their child’s HIV status with others. Thus, implications for pediatric adherence among study participants may be more favorable than the normal. Although this study focused on the multi-level challenges that administration of pediatric HIV ART presents to caregivers and health systems, many of the individual level challenges can be translated to other forms of chronic illness and their treatment plans.

5.0 Conclusion

These findings highlight the many challenges that caregivers face in providing ART to their childing living with HIV and highlight the need for improved formulations for pediatric ART to ease the daily burden on caregivers and children to increase adherence, improve child health, and overall quality of life of families.

Acknowledgments

We would like to thank the caregivers and providers who participated in the discussion and without whom these results would not be possible.

Data Availability

Data cannot be shared publicly, per restrictions set in place by the Institutional Review Boards at the University of Kansas Medical Center and University of Nairobi. Data can be requested at mdiniz@kumc.edu.

Funding Statement

This study was funded by the National Institute of Child Health and Human Development, award number R21HD105534 awarded to Dr. Sarah Finocchario-Kessler. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd ed. 2016. [PubMed] [Google Scholar]
  • 2.UNAIDS. Global HIV & AIDS statistics—Fact sheet. 2021. [Google Scholar]
  • 3.Ministry of Health. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV infection in Kenya. 2018. [Google Scholar]
  • 4.Muri L, Gamell A, Ntamatungiro AJ, Glass TR, Luwanda LB, Battegay M, et al. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern. Aids. 2017;31(1):61–70. doi: 10.1097/QAD.0000000000001273 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ateba Ndongo F, Texier G, Ida Penda C, Tejiokem MC, Tetang Ndiang S, Ndongo JA, et al. Virologic Response to Early Antiretroviral Therapy in HIV-infected Infants: Evaluation After 2 Years of Treatment in the Pediacam Study, Cameroon. Pediatr Infect Dis J. 2018;37(1):78–84. doi: 10.1097/INF.0000000000001745 [DOI] [PubMed] [Google Scholar]
  • 6.van Elsland SL, Peters RPH, Grobbelaar N, Ketelo P, Kok MO, Cotton MF, et al. Paediatric ART Adherence in South Africa: A Comprehensive Analysis. AIDS Behav. 2019;23(2):475–88. doi: 10.1007/s10461-018-2235-x [DOI] [PubMed] [Google Scholar]
  • 7.Schlatter AF, Deathe AR, Vreeman RC. The Need for Pediatric Formulations to Treat Children with HIV. AIDS Research and Treatment. 2016;2016:1654938. doi: 10.1155/2016/1654938 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Nahirya-Ntege P, Cook A, Vhembo T, Opilo W, Namuddu R, Katuramu R, et al. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PLoS One. 2012;7(5):e36186. doi: 10.1371/journal.pone.0036186 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lin D, Seabrook JA, Matsui DM, King SM, Rieder MJ, Finkelstein Y. Palatability, adherence and prescribing patterns of antiretroviral drugs for children with human immunodeficiency virus infection in Canada. Pharmacoepidemiol Drug Saf. 2011;20(12):1246–52. doi: 10.1002/pds.2236 [DOI] [PubMed] [Google Scholar]
  • 10.Ngarina M, Tarimo EA, Naburi H, Kilewo C, Mwanyika-Sando M, Chalamilla G, et al. Women’s preferences regarding infant or maternal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV during breastfeeding and their views on Option B+ in Dar es Salaam, Tanzania. PLoS One. 2014;9(1):e85310. doi: 10.1371/journal.pone.0085310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kekitiinwa A, Musiime V, Thomason MJ, Mirembe G, Lallemant M, Nakalanzi S, et al. Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antivir Ther. 2016;21(7):579–85. doi: 10.3851/IMP3054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Ministry of Health NASCP. Kenya HIV Prevention and Treatment Guidelines, 2022. Nairobi, Kenya; 2022. [Google Scholar]
  • 13.Vreeman RC, Nyandiko WM, Liu H, Tu W, Scanlon ML, Slaven JE, et al. Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya. J Int AIDS Soc. 2014;17(1):19227. doi: 10.7448/IAS.17.1.19227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Haas AD, Zaniewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, et al. Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. J Int AIDS Soc. 2018;21(2). doi: 10.1002/jia2.25084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2009;6(4):194–200. doi: 10.1007/s11904-009-0026-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Njuguna I, Beima-Sofie K, Mburu C, Mugo C, Black DA, Neary J, et al. Managing the transition from paediatric to adult care for HIV, Kenya. Bull World Health Organ. 2019;97(12):837–45. doi: 10.2471/BLT.19.232702 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.HIV.gov. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection 2023. [Available from: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/adherence-antiretroviral-therapy-children-and-adolescents-living-hiv. [Google Scholar]
  • 18.Olds PK, Kiwanuka JP, Ware NC, Tsai AC, Haberer JE. Explaining Antiretroviral Therapy Adherence Success Among HIV-Infected Children in Rural Uganda: A Qualitative Study. AIDS Behav. 2015;19(4):584–93. doi: 10.1007/s10461-014-0924-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Galea JT, Wong M, Muñoz M, Valle E, Leon SR, Díaz Perez D, et al. Barriers and facilitators to antiretroviral therapy adherence among Peruvian adolescents living with HIV: A qualitative study. PLOS ONE. 2018;13(2):e0192791. doi: 10.1371/journal.pone.0192791 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297–307. doi: 10.1093/cid/ciu046 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Clay PG, Nag S, Graham CM, Narayanan S. Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens. Medicine (Baltimore). 2015;94(42):e1677. doi: 10.1097/MD.0000000000001677 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pantuzza LL, Ceccato M, Silveira MR, Junqueira LMR, Reis AMM. Association between medication regimen complexity and pharmacotherapy adherence: a systematic review. Eur J Clin Pharmacol. 2017;73(11):1475–89. doi: 10.1007/s00228-017-2315-2 [DOI] [PubMed] [Google Scholar]
  • 23.Griffith DC, Farmer C, Gebo KA, Berry SA, Aberg J, Moore RD, et al. Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research Network. HIV Med. 2019;20(2):169–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Musiime V, Fillekes Q, Kekitiinwa A, Kendall L, Keishanyu R, Namuddu R, et al. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children. J Acquir Immune Defic Syndr. 2014;66(2):148–54. doi: 10.1097/QAI.0000000000000135 [DOI] [PubMed] [Google Scholar]
  • 25.Garg U, Rohtagi P, Singh G, Jain N, Pandey M, Kaul S, et al. Revolutionizing pediatric HIV therapy: The latest breakthroughs in drug delivery techniques. Journal of Drug Delivery Science and Technology. 2023;85:104618. [Google Scholar]
  • 26.Landovitz RJ, Li S, Eron JJ Jr, Grinsztejn B, Dawood H, Liu AY, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–e81. doi: 10.1016/S2352-3018(20)30106-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.McFarland EJ, Cunningham CK, Muresan P, Capparelli EV, Perlowski C, Morgan P, et al. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. J Infect Dis. 2021;224(11):1916–24. doi: 10.1093/infdis/jiab229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents. Clinical Infectious Diseases. 2022;75(Supplement_4):S562–S70. doi: 10.1093/cid/ciac754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Lowenthal E, Chapman J, Calabrese K, editors. Adolescent and parent experiences with long-acting injectables in the MOCHA study. Conference on Retroviruses and Opportunistic Infections, virtual; 2022. [Google Scholar]
  • 30.Li S, Li W, Prausnitz M. Individually coated microneedles for co-delivery of multiple compounds with different properties. Drug Deliv Transl Res. 2018;8(5):1043–52. doi: 10.1007/s13346-018-0549-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Penazzato M, Townsend CL, Sam-Agudu NA, Ruel TD, Archary M, Bekker A, et al. Advancing the prevention and treatment of HIV in children: priorities for research and development. Lancet HIV. 2022;9(9):e658–e66. doi: 10.1016/S2352-3018(22)00101-1 [DOI] [PubMed] [Google Scholar]
  • 32.Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76. doi: 10.4103/2230-973X.114897 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Finocchario-Kessler S, editor Developing Novel Alternative Delivery Strategies for Pediatric HIV Antiretroviral Therapy to Improve Adherence in Kenya. International Drug Discovery Science & Technology; 2023; the Netherlands. [Google Scholar]

Decision Letter 0

Adobea Yaa Owusu

19 Jun 2023

PONE-D-23-14403Challenges with pediatric antiretroviral therapy administration: qualitative perspectives from caregivers and HIV providers in KenyaPLOS ONE

Dear Dr. Wexler,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I emphasis making the following revisions, while attending to all the comments from both Reviewers, which I find valid:

Engage more relevant literature on the topic, restructure the results section and place the results within the context of previous work in this area.

Also, undertake detailed discussion of the findings, and not a repetition of the results. Further, thoroughly edit the grammar. Also, determine and specify who is a child, and who is not, in this study, and determine if this will change the title of your work, especially with reference to the word ‘pediatric’.

Thank you.

Academic Editor

Please ensure that your decision is justified on PLOS ONE’s publication criteria and not, for example, on novelty or perceived impact.

Please submit your revised manuscript by Aug 03 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Adobea Yaa Owusu, PhD MPH

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"We would like to thank the caregivers and providers who participated in the discussion and without whom these results would not be possible. This study was funded through the National Institute of Child Health and Human Development, Award R21HD105534."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"This study was funded by the National Institute of Child Health and Human Development, award number R21HD105534 awarded to Dr. Sarah Finocchario-Kessler. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Additional Editor Comments:

Dear Dr. Catherine Wexler,

I emphasis making the following revisions, while attending to all the comments from both Reviewers, which I find valid:

Engage more relevant literature on the topic, restructure the results section and place the results within the context of previous work in this area.

Also, undertake detailed discussion of the findings, and not a repetition of the results. Further, thoroughly edit the grammar. Also, determine and specify who is a child, and who is not, in this study, and determine if this will change the title of your work, especially with reference to the word ‘pediatric’.

Thank you.

Academic Editor

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: General Comment

This article explores an important area and provides insights into the challenges around ART Administration among children from caregivers and providers perspective. I found this to be a highly informative article with a rich results section. The article will benefit from restructuring of the results section and placing the results within the context of previous work in this area.

Specific comments

1. The authors should include where the study was conducted in the abstract and the methods section. This is missing and only appears in table 2, elsewhere the location is referred to as “three hospitals in Kenya” which is too general.

2. The methods section misses detail around how the study was conducted? Was the process iterative? Were the FGD guides refined between different FGDs? How many analysts coded?

3. For how many children had disclosure been done? This would be an important addition to the results section.

4. Table 2 would benefit from a clear description on the legend to help readers understand it.

5. The structure and classification in the results section is hard to follow. Authors need to refine this for clarity and better flow.

6. The discussion is plain and lacks detail. I worry that the article does not use the opportunity well to show the intersection of their results with prior work done in the same area. I notice articles that I would expect to be cited missing in this manuscript. The references in the article are much fewer that I would expect for this body of work. The authors should review available literature and include these to enrich their discussion. In the current state the discussion largely feels like a repetition of the results.

Reviewer #2: Thank you for an interesting manuscript that focuses on an important topic and provides an opportunity for caregivers and healthcare providers to share their perspectives. In my opinion, the manuscript is based on a study that was ethically considered, implemented, and reported. However, I have a few queries and suggestions for improvement of the manuscript.

Abstract

Results: Highlight what was reported by both groups (caregivers, healthcare providers) and then what was unique to each group.

Introduction

This section is well written but consider adding a paragraph that focuses on the current pediatric ART regimens in use in Kenya, and especially the region where you collected your data.

Comment: ‘In some cases, this also requires boiling water to make it potable, adding to the burden of ART preparation and administration for children.’ In addition, many Kenyan families struggle to get both water and fuel (e.g. kerosene, charcoal, firewood, gas).

Methods

Edit grammar here – ‘Participants were eligible to participate in focus group discussions if cared for child living with HIV…’

‘Caregivers included mothers, fathers, grandparents, or other family members serving as primary caregivers…’ Who are these other family members? Do you have this data? If yes, be explicit.

Consider using the COREQ checklist or any similar tool to help you report your study methodology fully. You are missing details and I will flag them as much as possible.

‘Caregivers were recruited … or providers with established relationships with clients at the study sites.’ What does this (established relationships with clients) mean?

‘Participants were eligible to participate in focus group discussions if cared … at one of the study hospitals.’

-You need to include information on the type of health facilities you used

-You need to report the number of facilities in the methodology chapter

-Justify use of the three facilities. Why 3 only? Why these particular 3 facilities?

‘Providers were eligible for interviews if they routinely participated in pediatric HIV care…’

-Did it matter how long they had been serving at the clinic or any other offering similar care?

-Can you add more information on the cadres of healthcare workers that were eligible?

‘Participants provided written informed consent in compliance with IRB approvals… for human subjects’ research.’ In this and all future research, consider using ‘human participants’ as opposed to ‘human subjects.’ The word ‘subject’ has over time been dropped in many settings because of its historical connotations and dehumanizing and disrespectful quality.

‘Immediately after informed consent was provided…’

-Add here details on the informed consent process. Step by step. Who did it? Where was it done? How was it done? And so on.

- Your study used other languages besides English. Add information on informed consent, translation and associated documents

Edit grammar here – ‘…surveys with each participant were conducted to capture socio-demographics characteristics or providers and caregivers.’

‘Surveys occurred in a private room and were conducted by a research assistant in English, Swahili, or Luo.’ This study has KIIs and FGDs. It is not clear what you are referring to here when you describe surveys.

Add all detail on the FGDs and KIIs. For example (and not conclusive):

-Where –venue- exactly were they done (and why there)?

-For each FGD, provide details on participants e.g. how many?

-For each FGD, how many facilitators were involved?

-Did you need to match facilitators to participant characteristics?

-Did you serve any refreshments?

-Did you provide any reimbursements to the participants?

‘Focus groups and interviews were audio recorded and transcribed verbatim.’ Your study used other languages besides English. Add information on translation?

‘Analysts met periodically to refine the codebook and develop consensus…’

-How many coders were involved?

‘Focus groups and KIIs lasted approximately 90 or 30 minutes, respectively.’

Move this sentence to the data collection section. It does not fit in the data analysis bit.

Results

‘The healthcare providers included… and others’

-Who are these in the category ‘other’? Be explicit.

‘About 76% of the caregivers were living with HIV.’

In Table 1, is ‘disclosure’ referring to disclosure about the child’s or the caregiver’s status? Clarify.

‘…who provided care for n=83 children (mean age 4.7 years old, range 5 months-18 years old)…’ Pg 9. 18-year-olds are defined as adults in Kenya.

In some sections, it is not clear whether the findings reported are from caregivers or healthcare providers. Ensure you do a thorough analysis of your findings. Presenting codes and themes is not adequate. Did findings differ with participant characteristics? Category of participants?

‘Types of Pediatric ART Regimens:

Participants described how ART medications…’

Which category of participants are you referring to here? Qualify. This applies in all sections of the results chapter where ‘participants’ are referred to generally.

‘Most caregivers did not have access to a refrigerator…’

Where is this type of data coming from?

‘Many described how their child would run…’

What is this referring to? A percentage of the FGDs?

Why is ‘poor taste’ discussed in two different sections? This is confusing. Consider exhaustively discussing one theme and then proceeding to the next.

‘Transcripts were coded based on a priori themes related to 1) individual-level considerations (e.g.,

knowledge and beliefs), 2) community-level considerations (e.g., privacy/confidentiality), 3) process of dosing (e.g., child refusal), and 4) environmental/system level considerations (e.g., frequency of medication refill).’ Pg 9.

Organize the findings chapter using these four distinct themes.

Some quotes are not in italics e.g. pg 12. Be consistent.

Edit grammar in this chapter e.g. ‘The topic of how access to information …’

Discussion

Ensure this chapter only discusses the findings from the results chapter.

Consider reporting them in four paragraphs guided by the reorganization of the results: 1) individual-level considerations, 2) community-level considerations, 3) process of, and 4) environmental/system level considerations.

‘We primarily focused on caregivers with young children living with HIV who required more complex administration with syrups or crushed tablets as their primary ART formulation.’

On Pg 9, you report that the children included 18-year-olds.

‘This paper is part one of a three-part study that aims to take information from these FGDs and provider interviews to create prototypes of oral dissolvable strips (ODS) for pediatric ART treatment…’

This information is needed at the end of the introduction

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Violet Naanyu

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Jan 9;19(1):e0296713. doi: 10.1371/journal.pone.0296713.r002

Author response to Decision Letter 0


29 Aug 2023

Dear reviewers and editor,

We appreciate your review of our manuscript and your extremely helpful comments to improve the clarity of the methods and the contextualization of the results. Per your recommendations, we have added details to the methods, tried to improve the organization of the results, and added details in the discussion to help contextualize our study within the broader literature around this topic. We believe these changes have significantly improved our manuscript and appreciate the time and effort that reviewers dedicated to their review.

A point-by-point response is included below.

Editor Comments

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

We have included the “inclusivity in global research” questionnaire in our submission.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"We would like to thank the caregivers and providers who participated in the discussion and without whom these results would not be possible. This study was funded through the National Institute of Child Health and Human Development, Award R21HD105534." We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: "This study was funded by the National Institute of Child Health and Human Development, award number R21HD105534 awarded to Dr. Sarah Finocchario-Kessler. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

We have removed funding information from the acknowledgements. The funding statement entered into the submission system is correct.

4. Engage more relevant literature on the topic, restructure the results section and place the results within the context of previous work in this area.

We have reorganized the results and added relevant literature and content to the discussion section to contextualize our finding more thoroughly within recent literature.

5. Also, undertake detailed discussion of the findings, and not a repetition of the results.

We have provided a more detailed discussion.

6. Further, thoroughly edit the grammar.

We have edited grammar.

7. Also, determine and specify who is a child, and who is not, in this study, and determine if this will change the title of your work, especially with reference to the word ‘pediatric’.

While we recognize that people 18 and older are legally adults, the caregiver to the 18-year-old “child” in this study, also cared for two younger children living with HIV: 9 months and 3 years; and, thus, met the eligibility criteria of the study. This grandparent talked about all three of her grandchildren during the survey and interview and, thus, we included the 18-year-old in the summary of caregiver characteristics. We have clarified this in the text. Given our focus on pediatric ART, we do not believe that this single older “child” necessitates a title change.

Reviewer 1

1. The authors should include where the study was conducted in the abstract and the methods section. This is missing and only appears in table 2, elsewhere the location is referred to as “three hospitals in Kenya” which is too general.

We have added the study hospitals in the main text, as well as the represented counties within the abstract.

2. The methods section misses detail around how the study was conducted? Was the process iterative? Were the FGD guides refined between different FGDs? How many analysts coded?

We have added details, per the CORE-Q checklist, to the methods section of the manuscript.

3. For how many children had disclosure been done? This would be an important addition to the results section.

We have added in that 20 out of the 83 children knew their HIV status.

4. Table 2 would benefit from a clear description on the legend to help readers understand it.

We have reformatted the tables to be clearer and easier to understand.

5. The structure and classification in the results section is hard to follow. Authors need to refine this for clarity and better flow.

We have re-organized the results to emphasize how regimen-related challenges create challenges in other dimensions of the participant’s life. The organization is briefly summarized in the “overview of results” section to justify this organization and orient the reader. We have also removed some of the subheadings which may have complicated the results. We hope this organization is easier to follow.

6. The discussion is plain and lacks detail. I worry that the article does not use the opportunity well to show the intersection of their results with prior work done in the same area. I notice articles that I would expect to be cited missing in this manuscript. The references in the article are much fewer that I would expect for this body of work. The authors should review available literature and include these to enrich their discussion. In the current state the discussion largely feels like a repetition of the results.

We have added content to the discussion to represent the current literature more thoroughly around pediatric ART and recent advances.

Reviewer #2:

Thank you for an interesting manuscript that focuses on an important topic and provides an opportunity for caregivers and healthcare providers to share their perspectives. In my opinion, the manuscript is based on a study that was ethically considered, implemented, and reported. However, I have a few queries and suggestions for improvement of the manuscript.

1. Results: Highlight what was reported by both groups (caregivers, healthcare providers) and then what was unique to each group.

Throughout the results we use the term “participant” when both caregivers and providers noted that theme; while the terms “caregiver” or “provider” is used to describe themes unique to each group. We have added a sentence at the beginning of the results to clarify this structure.

Introduction:

2. This section is well written but consider adding a paragraph that focuses on the current pediatric ART regimens in use in Kenya, and especially the region where you collected your data.

We have added a line in the intro outlining current first line ART, as well as availability of these ART as liquid or tablet formulations.

3. Comment: ‘In some cases, this also requires boiling water to make it potable, adding to the burden of ART preparation and administration for children.’ In addition, many Kenyan families struggle to get both water and fuel (e.g. kerosene, charcoal, firewood, gas).

We have added fuel costs as an additional burden.

Methods:

4. Edit grammar here – ‘Participants were eligible to participate in focus group discussions if cared for child living with HIV…’

Edited.

5. ‘Caregivers included mothers, fathers, grandparents, or other family members serving as primary caregivers…’ Who are these other family members? Do you have this data? If yes, be explicit.

This information is reported in Table 1.

6. Consider using the COREQ checklist or any similar tool to help you report your study methodology fully. You are missing details and I will flag them as much as possible.

We have modified the methods to include the COREQ checklist items and have included this in the resubmission packet.

7. ‘Caregivers were recruited … or providers with established relationships with clients at the study sites.’ What does this (established relationships with clients) mean?

We have specified that mentor mothers and providers who identified and recruited participants were part of the client’s clinical care team.

8. ‘Participants were eligible to participate in focus group discussions if cared … at one of the study hospitals.’

a. -You need to include information on the type of health facilities you used

b. -You need to report the number of facilities in the methodology chapter

c. -Justify use of the three facilities. Why 3 only? Why these particular 3 facilities?

We have added this information.

9. Providers were eligible for interviews if they routinely participated in pediatric HIV care…’

a. -Did it matter how long they had been serving at the clinic or any other offering similar care?

b. -Can you add more information on the cadres of healthcare workers that were eligible?

This has been included in new Table 2.

10. ‘Participants provided written informed consent in compliance with IRB approvals… for human subjects’ research.’ In this and all future research, consider using ‘human participants’ as opposed to ‘human subjects.’ The word ‘subject’ has over time been dropped in many settings because of its historical connotations and dehumanizing and disrespectful quality.

We have dropped this phrase from that sentence.

11. ‘Immediately after informed consent was provided…’

a. -Add here details on the informed consent process. Step by step. Who did it? Where was it done? How was it done? And so on.

b. - Your study used other languages besides English. Add information on informed consent, translation and associated documents

This information has been added.

12. Edit grammar here – ‘…surveys with each participant were conducted to capture socio-demographics characteristics or providers and caregivers.’

This has been corrected.

13. ‘Surveys occurred in a private room and were conducted by a research assistant in English, Swahili, or Luo.’ This study has KIIs and FGDs. It is not clear what you are referring to here when you describe surveys.

Per the sentence above, “surveys with each participant were conducted to capture socio-demographics characteristics of providers and caregivers.”

14. Add all detail on the FGDs and KIIs. For example (and not conclusive):

a. -Where –venue- exactly were they done (and why there)?

b. -For each FGD, provide details on participants e.g. how many?

c. -For each FGD, how many facilitators were involved?

d. -Did you need to match facilitators to participant characteristics?

e. -Did you serve any refreshments?

f. -Did you provide any reimbursements to the participants?

We have added this information into the methods section.

15. ‘Focus groups and interviews were audio recorded and transcribed verbatim.’ Your study used other languages besides English. Add information on translation?

We have added information on translation.

16. ‘Analysts met periodically to refine the codebook and develop consensus…’

a. -How many coders were involved?

We have added this information.

17. ‘Focus groups and KIIs lasted approximately 90 or 30 minutes, respectively.

a. Move this sentence to the data collection section. It does not fit in the data analysis bit.

This has been moved.

Results

18. ‘The healthcare providers included… and others’: Who are these in the category ‘other’? Be explicit.

We have included this information in new Table 2.

19. ‘About 76% of the caregivers were living with HIV: In Table 1, is ‘disclosure’ referring to disclosure about the child’s or the caregiver’s status? Clarify.

We have clarified within the table that it is referred to disclosure of the child’s HIV status to anyone but the caregiver involved in the FGD.

20. …who provided care for n=83 children (mean age 4.7 years old, range 5 months-18 years old)…’ Pg 9. 18-year-olds are defined as adults in Kenya.

While we recognize that people 18 and older are legally adults, the caregiver to the 18-year-old “child” in this study, also cared for two younger children living with HIV: 9 months and 3 years; and, thus, met the eligibility criteria of the study. This grandparent talked about all three of her grandchildren during the survey and interview and, thus, we included the 18-year-old in the summary of caregiver characteristics. We have clarified this in the text.

21. In some sections, it is not clear whether the findings reported are from caregivers or healthcare providers. Ensure you do a thorough analysis of your findings. Presenting codes and themes is not adequate. Did findings differ with participant characteristics? Category of participants?

There was significant alignment between caregiver and provider themes; thus, we presented many of them together to avoid duplication. Throughout the results we use the term “participant” when both caregivers and providers noted that theme; while “caregiver” or “provider” is used to describe themes unique to each group. We have added a sentence at the beginning of the results to clarify this structure.

22. ‘Types of Pediatric ART Regimens: Participants described how ART medications…’

Which category of participants are you referring to here? Qualify. This applies in all sections of the results chapter where ‘participants’ are referred to generally.

See response to query 21.

23. ‘Most caregivers did not have access to a refrigerator…’ Where is this type of data coming from?

We slightly modified this sentence because we do not have an exact count of the number with or without refrigerators. However, the theme of challenges with cool storage outside of refrigerator was mentioned 32 times by 14 participants. Of these, only one participant whose child’s medication needed to be kept cool spoke of owning a refrigerator, while others discussed keeping in jugs of cool water or using sand to keep the syrups cool.

24. ‘Many described how their child would run…’ What is this referring to? A percentage of the FGDs?

Child unease around medication administration was a strong theme, mentioned 32 times by caregivers in 8 of the 9 focus group discussions.

25. Why is ‘poor taste’ discussed in two different sections? This is confusing. Consider exhaustively discussing one theme and then proceeding to the next.

We have reorganized the results to remove headings and emphasize how regimen-related challenges created challenges in other aspects of the participant’s life.

26. ‘Transcripts were coded based on a priori themes related to 1) individual-level considerations (e.g.,

knowledge and beliefs), 2) community-level considerations (e.g., privacy/confidentiality), 3) process of dosing (e.g., child refusal), and 4) environmental/system level considerations (e.g., frequency of medication refill).’ Pg 9.: Organize the findings chapter using these four distinct themes.

We had initially done this; however, re-organized prior to initial submission because there was so much overlap between these various levels that we found ourselves repeating themes multiple times. For example, community level considerations (privacy, confidentiality, unintentional disclosure) were exacerbated significantly because children would run, cry and hide from the process of administration and this process of administration was so challenging because the drugs were so bitter, which is regimen-related characteristic. We found that while we may have coded that way, there was no simple and straight-forward way to separate these distinct levels as we discuss the broader context of pediatric ART administration. Thus, we have re-organized to emphasize how regimen-related challenges create challenges in other dimensions of the participant’s life. We have tried to simplify this organization and prep the reader more for it in our results section.

27. Some quotes are not in italics e.g. pg 12. Be consistent.

We’ve corrected this.

28. Edit grammar in this chapter e.g. ‘The topic of how access to information …’

This has been corrected.

Discussion

29. Ensure this chapter only discusses the findings from the results chapter.

We have gone through and reorganized the results and discussion to provide a more in-depth discussion of the implications of this research.

30. Consider reporting them in four paragraphs guided by the reorganization of the results: 1) individual-level considerations, 2) community-level considerations, 3) process of, and 4) environmental/system level considerations.

Please see response to comment #26 for reasoning behind our chosen organization.

31. ‘We primarily focused on caregivers with young children living with HIV who required more complex administration with syrups or crushed tablets as their primary ART formulation.’

On Pg 9, you report that the children included 18-year-olds.

We have clarified that the caregiver of the 18-year old also cared for young children. While the 18-year old was not inquired upon, the caregiver did include them as a child she cared for and, thus, we reported here.

32. ‘This paper is part one of a three-part study that aims to take information from these FGDs and provider interviews to create prototypes of oral dissolvable strips (ODS) for pediatric ART treatment…’ This information is needed at the end of the introduction

We have added this in the intro.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Petros Isaakidis

15 Nov 2023

PONE-D-23-14403R1Challenges with pediatric antiretroviral therapy administration: qualitative perspectives from caregivers and HIV providers in KenyaPLOS ONE

Dear Dr. Wexler,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 30 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Petros Isaakidis

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: ABSTRACT

-In your abstract, as you report findings, highlight what was reported by both groups (caregivers, healthcare providers) and then what was unique to each group. This is still pending.

-Consider having a conclusion, not a discussion section in the abstract.

METHODS

-Your study used other languages besides English. Add information on informed consent, translation and associated consenting documents. This is still pending.

-It is still not clear which findings come from which of the 9 FGDs and/or which of the KIIs. I suggest you get 3 index refereed articles to guide you in your data analyses and reporting. You need to:

*Run analysis for the 9 FGDs

*Run analysis for each of the 30 KIIs

*Run a summary that shows your findings by each of the 3 sites

*It would also help to run a summary that shows codes/sub codes by caregiver characteristics

Then do a comparative analysis. I find it easier to use a visual- a summary matrix during my data management and analysis. For such a study, it would have 39 columns to capture all the codes/sub-codes from all the data collection sessions. It makes comparison easier.

-Edit grammar in this section.

RESULTS

-Ensure all content provided in Table 1 is reported in narrative format. This is still pending. This guideline applies where all tables are concerned.

- You continue to provide sections of transcripts as data findings. This is still pending.

Do findings differ by sites? FGDs? KIIs? Demographics - especially care giver characteristics?

DISCUSSION

-This section has improved. Thank you

-Once you revise the results section, refine the discussion and conclusion sections.

CONCLUSION

-Add a conclusion in this manuscript.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: Yes: VIOLET NAANYU

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Jan 9;19(1):e0296713. doi: 10.1371/journal.pone.0296713.r004

Author response to Decision Letter 1


11 Dec 2023

1. In your abstract, as you report findings, highlight what was reported by both groups (caregivers, healthcare providers) and then what was unique to each group. This is still pending.

We have specified which results came from which participant group.

2. Consider having a conclusion, not a discussion section in the abstract.

We have changed discussion to “conclusion” in the abstract.

METHODS

3. Your study used other languages besides English. Add information on informed consent, translation and associated consenting documents. This is still pending.

We have specified that: “Participants provided written informed consent in compliance with IRB approvals at the University of Kansas Medical Center (STUDY00147024) and University of Nairobi (P457/06/2021). Caregiver informed consent documents and FGD guides were available in English, Luo, and Swahili and all documents and translations were approved by the IRB at the University of Nairobi. Provider informed consent documents and interview guides were available in English only, as all healthcare providers were fluent in English. During the informed consent process, the interviewer explained the purpose of the study, risks, and benefits of the study, and emphasized that study participant was optional. Immediately after informed consent was provided but prior to the focus groups or KIIs, surveys with each participant were conducted to capture socio-demographics characteristics of providers and caregivers. Informed consent interviews and surveys occurred in a private area of the hospital and were conducted by a research assistant in English, Swahili, or Luo, per the participant’s preference. “ We have added a line that specifies caregiver documents were available in 3 languages and that all documents and translations were approve by the IRB at a local institution.

4. It is still not clear which findings come from which of the 9 FGDs and/or which of the KIIs. I suggest you get 3 index refereed articles to guide you in your data analyses and reporting. You need to:

*Run analysis for the 9 FGDs

*Run analysis for each of the 30 KIIs

*Run a summary that shows your findings by each of the 3 sites

*It would also help to run a summary that shows codes/sub codes by caregiver characteristics

Then do a comparative analysis. I find it easier to use a visual- a summary matrix during my data management and analysis. For such a study, it would have 39 columns to capture all the codes/sub-codes from all the data collection sessions. It makes comparison easier.

The objective of this study was to assess general challenges to pediatric ART in Kenya to inform development of a product that could overcome these challenges. While we included multiple caregiver types to represent the range of caregivers who provide care to children living with HIV, we did not intend to analyze differences between caregiver types. That said, there was great consensus across the concerns raised. We feel that such a quantitative approach to this qualitative study is unnecessary given the consensus.

5. Edit grammar in this section.

We have edited the grammar to standard English.

RESULTS

6. Ensure all content provided in Table 1 is reported in narrative format. This is still pending. This guideline applies where all tables are concerned.

The paragraph proceeding the tables summarizes key items in the table without being redundant of the information in the table. We feel that adding more descriptive text would not add meaningful content to the manuscript and would be duplicative of the information provided in the table.

7. You continue to provide sections of transcripts as data findings. This is still pending.

Per the COREQ guidelines, which we have attached as a supplementary material and complies with journal requirements, item 29 requires participant quotations to highlight themes and findings. We have opted to retain these quotations as required by journal guidelines and as the accepted practice in qualitative data presentation.

8. Do findings differ by sites? FGDs? KIIs? Demographics - especially care giver characteristics?

Per response above: The objective of this study was to assess general challenges to pediatric ART in Kenya to inform development of a product that could overcome these challenges. While we included multiple caregiver types to represent the range of caregivers who provide care to children living with HIV, we did not intend to analyze differences between caregiver types. That said, there was great consensus across the concerns raised. We feel that such a quantitative approach to this qualitative study is unnecessary given the consensus.

DISCUSSION

9. This section has improved. Thank you

Once you revise the results section, refine the discussion and conclusion sections.

We have opted not to revise the results section, as discussed above.

CONCLUSION

10. Add a conclusion in this manuscript.

We have added a conclusion to this manuscript.

Attachment

Submitted filename: Response to review comments_3.docx

Decision Letter 2

Petros Isaakidis

18 Dec 2023

Challenges with pediatric antiretroviral therapy administration: qualitative perspectives from caregivers and HIV providers in Kenya

PONE-D-23-14403R2

Dear Dr. Wexler,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Petros Isaakidis MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I fully support your decision to maintain the quotes in the manuscript (excellent response), and I also did appreciate your response about the comparisons between groups.

Reviewers' comments:

Acceptance letter

Petros Isaakidis

28 Dec 2023

PONE-D-23-14403R2

PLOS ONE

Dear Dr. Wexler,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Petros Isaakidis

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to review comments_3.docx

    Data Availability Statement

    Data cannot be shared publicly, per restrictions set in place by the Institutional Review Boards at the University of Kansas Medical Center and University of Nairobi. Data can be requested at mdiniz@kumc.edu.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES